AMAG Pharmaceuticals (NASDAQ:AMAG) has received a short term rating of strong sell from experts at Zacks with a rank of 5. The stock has been rated an average of 2 by 8 Brokerage Firm. 4 Wall Street Firms have rated the stock as a strong buys. 4 Brokerage Firms have advised hold.
Other Equity analysts have also commented on the company shares. Equity Analysts at the Brokerage Firm, Raymond James, downgrades their rating on the shares of AMAG Pharmaceuticals (NASDAQ:AMAG). Raymond James has a Market Perform rating on the shares. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on May 4, 2016.
AMAG Pharmaceuticals (NASDAQ:AMAG): 7 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $46.29 in AMAG Pharmaceuticals (NASDAQ:AMAG). However, the stock price could fluctuate by $ 18.15 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $80 price target with the lower price estimate is calculated at $27
AMAG Pharmaceuticals (NASDAQ:AMAG) witnessed a decline in the market cap on Tuesday as its shares dropped 0.04% or 0.01 points. After the session commenced at $23.74, the stock reached the higher end at $23.92 while it hit a low of $23.0768. With the volume soaring to 903,320 shares, the last trade was called at $23.63. The company has a 52-week high of $77.73. The company has a market cap of $817 million and there are 34,578,855 shares in outstanding. The 52-week low of the share price is $17.92.
Shares of AMAG Pharmaceuticals, Inc. rose by 2.87% in the last five trading days and 24.63% for the last 4 weeks. AMAG Pharmaceuticals, Inc. is up 8.74% in the last 3-month period. Year-to-Date the stock performance stands at -21.73%.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.